Curonix Partners with Sure Med Compliance to Expand PNS Clinical Evidence
January 18, 2024 08:00 ET
|
Curonix LLC
Curonix Partners with Sure Med Compliance to Expand PNS Clinical Evidence
New SPR Therapeutics Data Presented at ASRA Pain Medicine Meeting 2023
November 13, 2023 09:05 ET
|
SPR Therapeutics, Inc.
Three SPR Posters Accepted Including a President’s Choice Award for New Data from Randomized Controlled Trial on Total Knee Replacement Postoperative Pain
Curonix Celebrates 1st Anniversary
November 01, 2023 09:00 ET
|
Curonix LLC
POMPANO BEACH, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Today, Curonix LLC, a leading peripheral nerve stimulation company celebrated its first anniversary. In November 2022, Curonix completed the...
Independent clinical study shows Curonix’s Freedom® PNS System significantly reduces pain scores and medication usage
June 07, 2023 07:00 ET
|
Curonix LLC
POMPANO BEACH, Fla., June 07, 2023 (GLOBE NEWSWIRE) -- Curonix LLC, a medical technology company dedicated to freeing patients from chronic pain, announced the publication of 24 months of data from...
SelectHealth Initiates Peripheral Nerve Stimulation (PNS) Coverage to Support Patient Need for Effective Non-opioid Pain Treatment
May 04, 2023 11:07 ET
|
SPR Therapeutics, Inc.
CLEVELAND, May 04, 2023 (GLOBE NEWSWIRE) -- SelectHealth, a non-profit health plan with over one million members, has demonstrated leadership amid the opioid crisis by creating one of the first...
SPR Therapeutics to Present Clinical Trial and Real-World Findings at ASPN 2022
July 14, 2022 10:54 ET
|
SPR Therapeutics, Inc.
CLEVELAND, July 14, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced today that two presentations highlighting SPRINT® PNS in treating chronic pain will be featured at the American Society of...
SPR Therapeutics Announces 10,000th SPRINT PNS Procedure for Patients Suffering from Life-altering Pain
May 12, 2022 09:00 ET
|
SPR Therapeutics, Inc.
CLEVELAND, May 12, 2022 (GLOBE NEWSWIRE) -- Cleveland based medical device company SPR Therapeutics today announced a key milestone with the 10,000th patient treated using the SPRINT® PNS System....
Real-world Study of SPRINT 60-day Peripheral Nerve Stimulation (PNS) Corroborates Published Clinical Study Results
May 06, 2022 09:24 ET
|
SPR Therapeutics, Inc.
CLEVELAND, May 06, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced the publication of a study that evaluated the real-world impact of 60-day peripheral nerve stimulation (PNS) in the management...
The PNS Trifecta: All Three SPRINT® PNS System Abstracts Submitted to ASRA 2021 Pain Medicine Meeting Receive President’s Choice Award
November 18, 2021 12:32 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics has been honored with three President’s Choice Abstract Awards at the 20th Annual ASRA Pain Medicine Meeting taking place November 18-20...
FDA Clearance of an Expanded Indication for the SPRINT® PNS System Now Enables Treatment in Areas of the Head, Neck, and Torso
October 19, 2021 12:22 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Ohio, Oct. 19, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics® has obtained clearance from the U.S. Food and Drug Administration (FDA) of a broader indication for use for its SPRINT Peripheral...